Global Targeted PSMA Radionuclide Drug Conjugates Market 2026 by Company, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Targeted PSMA Radionuclide Drug Conjugates market size was valued at US$ 2052 million in 2025 and is forecast to a readjusted size of US$ 3466 million by 2032 with a CAGR of 7.5% during review period.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis’ Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
This report is a detailed and comprehensive analysis for global Targeted PSMA Radionuclide Drug Conjugates market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted PSMA Radionuclide Drug Conjugates
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted PSMA Radionuclide Drug Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Telix Pharmaceuticals, Lantheus, Fusion Pharmaceuticals, Blue Earth Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted PSMA Radionuclide Drug Conjugates market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monotherapy Products
Combination Therapy Products
Market segment by Radionuclide Type
Beta-emitting
Alpha-emitting
Other
Market segment by Targeting Vector Type
Small-molecule
Antibody-based
Other
Market segment by Application
Hospital
Clinic
Others
Market segment by players, this report covers
Novartis
Curium
Telix Pharmaceuticals
Lantheus
Fusion Pharmaceuticals
Blue Earth Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted PSMA Radionuclide Drug Conjugates product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted PSMA Radionuclide Drug Conjugates, with revenue, gross margin, and global market share of Targeted PSMA Radionuclide Drug Conjugates from 2021 to 2026.
Chapter 3, the Targeted PSMA Radionuclide Drug Conjugates competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted PSMA Radionuclide Drug Conjugates market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted PSMA Radionuclide Drug Conjugates.
Chapter 13, to describe Targeted PSMA Radionuclide Drug Conjugates research findings and conclusion.